Alzheimer?s disease (AD) is a devastating progressive neurodegenerative disorder affecting >6 million older people in the USA for which there is no viable treatment option. Accordingly, defining the earliest cellular and molecular mechanisms that drive the preclinical phase of dementia to develop novel disease modifying therapeutics is a public health priority worldwide. The thrust of our PPG entitled ?Neurobiology of Mild Cognitive Impairment in the Elderly? continues to be to elucidate the cellular and molecular basis or chain of events leading from no cognitive impairment (NCI) to mild cognitive impairment (MCI), the time-points considered the most likely therapeutic windows for treating dementia. Moreover, we continue to focus our efforts on NCI subjects with AD pathology suggestive of preclinical AD, in order to resolve the molecular and cellular neuropathogenic sequela underlying this preclincal stage of the disease. We will implement a series of interrelated connectome projects centered on the cholinergic basal forebrain (CBF)-default mode network (DMN) circuit, which is critical for memory and executive function and displays early pathology and biomaker activity prior to MCI (prodromal AD). CBF neuron dysfunction plays a pivotal role in the onset of clinical dementia and is the basis for the majority of FDA approved drugs for AD. This PPG competitive renewal application continues to bring together a number of basic and clinical scientists with multidisciplinary, complementary expertise in preclinical AD to investigate circuit-based neuronal system dysfunction at the earliest stages in the disease process. The PPG includes an Administrative & Clinical/Tissue Distribution Core, a Statistics & Data Management Core and three research projects titled: Tau Abnormalities and Mild Cognitive Impairment in the Elderly Scott Counts, Project Leader, PL, Michigan State University, Cholinergic Basal Forebrain Neurotrophic Abnormalities and Mild Cognitive Impairment in the Elderly (Elliott Mufson, PL, Barrow Neurologic Institute/Banner Alzheimer?s Institute), and Synaptic and Cholinergic Abnormalities in Mild Cognitive Impairment in the Elderly (Milos Ikonomovic, PL University of Pittsburgh). The Cores support each Project and all Projects interact intellectually, scientifically, and thematically. All Cores and Projects utilize the same Rush Religious Orders Study (RROS) cases and tissues for continuity, which confers the ability to correlate biologic measures with cognitive and neuropathological criterion. The lack of true animal models and a lack of efficacy of current drugs make our human clinical pathological studies particularly relevant for understanding mechanisms of preclinical AD.

Public Health Relevance

This program renewal will provide a greater understanding of the pathogenesis of a critical brain network that modulates cognitive function by identifying connectome deficits during preclinical Alzheimer?s disease (AD) so early treatment strategies can be implemented. Proposed studies are relevant to the NIA mission supporting research to define the cellular and molecular biology of dementia at the earliest stage of onset, which provide targets for transcriptionally aided drug discovery at a time when no treatments exist for AD.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Opanashuk, Lisa A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
St. Joseph's Hospital and Medical Center
United States
Zip Code
Peng, Katherine Y; Pérez-González, Rocío; Alldred, Melissa J et al. (2018) Apolipoprotein E4 genotype compromises brain exosome production. Brain :
Ginsberg, Stephen D; Alldred, Melissa J; Gunnam, Satya M et al. (2018) Expression profiling suggests microglial impairment in human immunodeficiency virus neuropathogenesis. Ann Neurol 83:406-417
Tiernan, Chelsea T; Ginsberg, Stephen D; He, Bin et al. (2018) Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease. Neurobiol Dis 117:125-136
Kaur, Gurjinder; Gauthier, Sebastien A; Perez-Gonzalez, Rocio et al. (2018) Cystatin C prevents neuronal loss and behavioral deficits via the endosomal pathway in a mouse model of down syndrome. Neurobiol Dis 120:165-173
Jansen, Willemijn J; Wilson, Robert S; Visser, Pieter Jelle et al. (2018) Age and the association of dementia-related pathology with trajectories of cognitive decline. Neurobiol Aging 61:138-145
Tiernan, Chelsea T; Mufson, Elliott J; Kanaan, Nicholas M et al. (2018) Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease. J Neuropathol Exp Neurol 77:246-259
Krivinko, Josh M; Erickson, Susan L; Ding, Ying et al. (2018) Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease. Am J Psychiatry 175:999-1009
Malek-Ahmadi, Michael; Chen, Kewei; Perez, Sylvia E et al. (2018) Cognitive composite score association with Alzheimer's disease plaque and tangle pathology. Alzheimers Res Ther 10:90
Edler, Melissa K; Sherwood, Chet C; Meindl, Richard S et al. (2018) Microglia changes associated to Alzheimer's disease pathology in aged chimpanzees. J Comp Neurol 526:2921-2936
Mahady, Laura; Nadeem, Muhammad; Malek-Ahmadi, Michael et al. (2018) Frontal Cortex Epigenetic Dysregulation During the Progression of Alzheimer's Disease. J Alzheimers Dis 62:115-131

Showing the most recent 10 out of 293 publications